DDrare: Database of Drug Development for Rare Diseases

Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2387066; 3400935113276; 8699505952864; AIN457; APREMILAST; Adalimumab; Allogeneic Stem Cell Transplant; Alpha interferon; Anakinra; Apremilast; Apremilast (CC-10004); Autologous Stem Cell Transplant; Autologous Stem Cell Transplantation; BFGF; CANAKINUMAB; CC; CC-10004; Calcium; Canakinumab; Colchicine; Cyclophosphamide; Cyclosporin; Cyclosporin A; Cyclosporine; Cyclosporine Pill; Cytotoxic Combination; Daclizumab; Dextrose; Entecavir; Etanercept; Etanercept, Methotrexate, Prednisolone; Flucinolone acetonide; GEVOKIZUMAB; GSK1070806; Gevokizumab; Golimumab; Golimumab (GOL); Hemay005; Hydroxychloroquine; IL-2; INTERLEUKIN 2; Ilaris; Infliximab; Interferon Alfa-2A; Interferon alfa; Interferon alfa-2a; Interferon alpha-2a; Interferon-alpha2a; Interleukin 2; Intravitreal Infliximab; J1081; Low-dose IL-2; Methotrexate; Methylorednisolone; Otezla; Other: dextrose water 5%; Other: serum levels of angiogenin, bFGF, VEGF; Pentoxifylline; Prednisolone; Radiation: Diode laser 980nm&100 mWatt; Remicade; Remicade 100 mg; RhumAb to Il-17A (IgG1-k-class); Rituximab; Roferon-A; Roferon-A 3miu; Roferon-A, 3miu; Roferon-A, 4.5miu; Roferon-A, 6miu; Rosuvastatin; Rosuvastatin calcium 40mg; S78989; STELARA; Stelara; Subcutaneous Ustekinumab; TA-650; Thalidomide; Tocilizumab; Tocilizumab (TCZ); Topical Pentoxifylline Gel (Vehicle +PTX); Triamcinolone; Triamcinolone Acetonide; Ustekinumab; Veldona; Veldona,; Water; XOMA 052

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00720928 (ClinicalTrials.gov)	July 2008	18/7/2008	Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease	A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease	Ocular Behcet's Disease,;Non-Infectious Uveitis;Refractory Uveitis	Drug: flucinolone acetonide	Asan Medical Center	Samsung Medical Center;Seoul National University Hospital;Kyunghee University Medical Center	Recruiting	18 Years	N/A	Both	15	Phase 4	Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00720928
(ClinicalTrials.gov)

July 2008

18/7/2008

Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease

A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease

Ocular Behcet's Disease,;Non-Infectious Uveitis;Refractory Uveitis

Drug: flucinolone acetonide

Asan Medical Center

Samsung Medical Center;Seoul National University Hospital;Kyunghee University Medical Center

Recruiting

18 Years

N/A

Both

Phase 4

Korea, Republic of